%0 Journal Article
%T Reduction in HbA1c using professional flash glucose monitoring in insulin
%A Neil Jackson
%A Ramzi A Ajjan
%A Scott A Thomson
%J Diabetes and Vascular Disease Research
%@ 1752-8984
%D 2019
%R 10.1177/1479164119827456
%X Analyse the effects of professional flash glucose monitoring system (FreeStyle Libre Pro£¿) on glycaemic control in insulin-treated type 2 diabetes. Primary (n£¿=£¿17) and secondary care centres (n£¿=£¿5) randomised 148 type 2 diabetes patients into three groups: (A) self-monitoring of blood glucose (n£¿=£¿52), (B) self-monitoring of blood glucose and two Libre Pro sensor wears (n£¿=£¿46) or (C) self-monitoring of blood glucose and four sensor wears (n£¿=£¿50). Primary endpoint was time in range (glucose 3.9¨C10£¿mmol/L) within group C comparing baseline with days 172¨C187. Predefined secondary endpoints included HbA1c, hypoglycaemia and quality of life measures analysed within and between groups (clinicaltrials.gov, NCT02434315). In group C, time in range in the first 14£¿days (baseline) and days 172¨C187 was similar at 15.0£¿¡À£¿5.0 and 14.1£¿¡À£¿4.7£¿h/day (mean£¿¡À£¿SD), respectively, (p£¿=£¿0.1589). In contrast, HbA1c reduced from baseline to study end within group C by 4.9£¿¡À£¿8.8£¿mmol/mol (0.44%£¿¡À£¿0.81%; p£¿=£¿0.0003). HbA1c was also lower in group C compared with A at study end by 5.4£¿¡À£¿1.79£¿mmol/mol (0.48%£¿¡À£¿0.16%; p£¿=£¿0.0041, adjusted mean ¡À SE), without increased time in hypoglycaemia (p£¿=£¿0.1795). Treatment satisfaction scores improved in group C compared with A (p£¿=£¿0.0225) and no device-related serious adverse events were reported. Libre Pro can improve HbA1c and treatment satisfaction without increasing hypoglycaemic exposure in insulin-treated type 2 diabetes individuals managed in primary/secondary care centres
%K Continuous glucose monitoring
%K flash glucose monitoring
%K HbA1c
%K hypoglycaemia
%K hyperglycaemia
%K glycaemic variability
%U https://journals.sagepub.com/doi/full/10.1177/1479164119827456